Citius Oncology (CTOR) Net Cash Flow (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Net Cash Flow data on file, last reported at -$4.7 million in Q1 2026.

• On a quarterly basis, Net Cash Flow changed N/A year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$1.3 million, a 3807.81% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, up 3504182.14% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.7 million, down from $3.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for CTOR reached as high as $3.4 million in Q4 2025 and fell as low as -$4.7 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$265209.4 across 4 years, with a median of -$100256.0 in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 100.35% in 2024 and fell as far as 67.02% in 2024.
• Year by year, Net Cash Flow stood at -$262652.0 in 2023, then jumped by 87.41% to -$33069.0 in 2024, then surged by 10292.46% to $3.4 million in 2025, then tumbled by 238.34% to -$4.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$4.7 million in Q1 2026, $3.4 million in Q4 2025, and -$33069.0 in Q2 2024.